Modelling Tau Distribution From DTI With Generative Adversarial Network for Alzheimer's Disease Diagnosis

Launched by CHINESE UNIVERSITY OF HONG KONG · Aug 23, 2021

Keywords

ClinConnect Summary

This clinical trial is exploring a new method to help diagnose Alzheimer's disease by using advanced computer technology. Researchers are developing a system that can create synthetic images showing the buildup of tau protein in the brain, which is a key feature of Alzheimer's. Instead of using traditional imaging techniques that involve radiation, this new approach uses magnetic resonance imaging (MRI) data to produce these images, making it safer and potentially more accessible for patients.

To participate in this study, individuals must be 55 years or older and have had a brain MRI within six months of being diagnosed with Alzheimer's, mild cognitive impairment (MCI), or having normal cognitive function. Unfortunately, those with certain types of dementia, severe brain injuries, or other serious health issues won't be eligible. If you join this trial, you can help researchers develop an innovative tool that could improve how doctors identify and understand Alzheimer's disease, ultimately benefiting both clinical practice and research in this area.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • With the age of 55 years and above
• • With brain MRI taken within ±6 months from the date of clinically confirmed diagnosis of AD, MCI or normal cognition.
• Exclusion Criteria:
• • AD with mixed dementia
• • Non-AD dementia
• • History of severe traumatic brain injury, severe depression, stroke, brain tumors, and incident major systemic illness